EQT AB (publ) (EQBBF)
| Previous Close | 26.00 |
| Open | 26.00 |
| Bid | 25.50 x 40000 |
| Ask | 27.60 x 40700 |
| Day's Range | 26.00 - 26.00 |
| 52 Week Range | 20.44 - 36.15 |
| Volume | |
| Avg. Volume | 518 |
| Market Cap | 31.755B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | 96.30 |
| EPS (TTM) | 0.27 |
| Earnings Date | Oct 17, 2024 |
| Forward Dividend & Yield | 0.33 (1.28%) |
| Ex-Dividend Date | Nov 29, 2024 |
| 1y Target Est | N/A |
PR NewswireEQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round is aimed at accelerating the clinical development of a groundbreaking therapeutic antibody pipeline derived from its proprietary ATBioFarm platform. The financing was co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, a corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA) alongside contributions from V-Bio, VIVES Partners, the Belgian sovereign fun
PR NewswireEQT Exeter to Acquire Strategic Supply Chain Assemblage Comprising Nearly Five Million Square Feet of Institutional Quality Industrial Assets
EQT Exeter, a leading global real estate investment manager, is pleased to announce that the EQT Exeter Industrial Value Fund VI ("EQT Exeter") has acquired 33 industrial assets ("the Assemblage") strategically located in prime submarkets across the United States. Twenty-one of the assets are located in markets with an EQT Exeter office.
